Hsbc Holdings PLC Sells 44,923 Shares of CureVac (NASDAQ:CVAC)

Hsbc Holdings PLC decreased its stake in shares of CureVac (NASDAQ:CVAC – Get Rating) by 45.9% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 52,961 shares of the company’s stock after selling 44,923 shares during the quarter. Hsbc Holdings PLC’s holdings in CureVac were worth $418,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in CVAC. Quadrant Capital Group LLC increased its holdings in shares of CureVac by 28.6% during the 2nd quarter. Quadrant Capital Group LLC now owns 3,769 shares of the company’s stock worth $51,000 after purchasing an additional 838 shares during the period. Amundi bought a new stake in CureVac in the second quarter valued at about $87,000. Virtus ETF Advisers LLC increased its stake in CureVac by 90.6% in the second quarter. Virtus ETF Advisers LLC now owns 7,676 shares of the company’s stock valued at $104,000 after acquiring an additional 3,648 shares during the period. SG Americas Securities LLC increased its stake in CureVac by 19.4% in the third quarter. SG Americas Securities LLC now owns 13,881 shares of the company’s stock valued at $109,000 after acquiring an additional 2,256 shares during the period. Finally, Quantamental Technologies LLC bought a new stake in CureVac in the second quarter valued at about $157,000.

CureVac Stock Performance

CureVac stock opened at $7.69 on Tuesday. The company has a quick ratio of 3.56, a current ratio of 3.61 and a debt-to-equity ratio of 0.06. The company has a fifty day simple moving average of $9.18 and a 200 day simple moving average of $8.53. CureVac has a 1-year low of $5.63 and a 1-year high of $20.49.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. JMP Securities lowered their target price on shares of CureVac from $37.00 to $34.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 17th. UBS Group upgraded shares of CureVac from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Thursday, January 19th. They noted that the move was a valuation call. Finally, Jefferies Financial Group upgraded shares of CureVac from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a report on Friday, January 6th.

CureVac Company Profile

(Get Rating)

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza.